Skip to main content
OpenTrials
Not Yet Recruiting

NCT Number: NCT07657442

Risk-Stratified Hypofractionated Radiotherapy After Breast-Conserving Surgery for Early Breast Cancer

This prospective study is designed to evaluate the feasibility, efficacy, and safety of risk-stratified hypofractionated radiotherapy after breast-conserving surgery in patients with early breast cancer.

Not Yet Recruiting

Trial opening soon.

Get Notified

Key information

Age range

18 year–75 year

Sex eligibility

Female

Study type

Interventional

Phase

Not applicable

Primary location

Cancer Hospital, Chinese Academy of Medical Sciences

Beijing, Beijing Municipality, 100021, China

Location contact

Shu-Lian Wang

CONTACT

[email protected]

8610-87788803

About this study

Eligible patients with early breast cancer who have undergone breast-conserving surgery will be stratified into a high-risk group or a low-risk group according to the presence or absence of predefined high-risk factors.

Patients in the high-risk group will receive whole-breast irradiation with a simultaneous integrated boost to the tumor bed. The prescribed dose will be 36 Gy in 15 fractions over 3 weeks to the whole breast and 48 Gy in 15 fractions over 3 weeks to the tumor bed.

Patients in the low-risk group will receive partial-breast irradiation. Two hypofractionated schedules may be used: 40.05 Gy in 15 fractions over 3 weeks or 26 Gy in 5 fractions over 1 week.

Patients will be followed during and after radiotherapy to evaluate treatment efficacy, recurrence rates, and acute and late radiation-related toxicities.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • ECOG performance status score of 0 to 2.
  • Pathologically confirmed breast cancer, including invasive carcinoma or ductal carcinoma in situ.
  • Clinical stage cT0-2N0M0.
  • Underwent breast-conserving surgery.
  • Negative surgical margins greater than 2 mm.

Exclusion criteria

  • Regional lymph node metastasis.
  • Distant metastasis.
  • Bilateral breast cancer.
  • Prior thoracic radiotherapy.
  • Life expectancy of less than 5 years.
  • Lactating or pregnant women.

Treatment and study plan

Whole-breast irradiation and tumor bed boost

Radiation

Whole-breast irradiation: 36 Gy in 15 fractions; Tumor bed boost: 48 Gy in 15 fractions

Partial-breast irradiation

Radiation

Partial-breast irradiation: 40.05 Gy in 15 fractions or 26 Gy in 5 fractions

Primary outcomes

  1. Local recurrence rate

    Time frame: Five years

    Ipsilateral breast recurrence rate

Secondary outcomes

  1. Disease-free survival rate

    Time frame: Five years

    Disease-free survival rate

  2. Radiation-related adverse events

    Time frame: Five years

    Adverse events

Study contacts

Contact information is provided by the study sponsor or research team.

Shu-Lian Wang, MD

CONTACT

[email protected]

8610-87788803

Sponsors and collaborators

Lead sponsor

Cancer Institute and Hospital, Chinese Academy of Medical Sciences

Other

Registry information

Official study title

A Prospective Study of Risk-Stratified Hypofractionated Radiotherapy After Breast-Conserving Surgery for Early Breast Cancer

Important dates

Study start
2026
Primary completion
2027
Study completion
2032
First posted
Jun 18, 2026
Registry last updated
Jun 18, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.